About Waylivra

Waylivra is the only therapy licensed to treat FCS as an adjunct to diet in adult patients, in whom diet and triglyceride lowering therapy has been inadequate¹

Waylivra inhibits formation of ApoC-III¹

In FCS, inherited LPL dysfunction prevents the metabolism of triglycerides (carried by chylomicrons) through the LPL-dependent pathway.²

• Waylivra is an antisense oligonucleotide that inhibits the production of apoC-III by binding to its mRNA and preventing its translation.¹
• By reducing apoC-III, Waylivra removes an inhibitor of triglyceride clearance, enabling triglyceride metabolism through an LPL-independent pathway in patients with FCS.¹